Navigation Links
Boston Scientific Statement on the Passing of Senator Edward Kennedy
Date:8/26/2009

NATICK, Mass., Aug. 26 /PRNewswire/ --

The statement below is from Pete Nicholas, Chairman of the Board of Boston Scientific Corporation, on behalf of the Company, its employees and its Board of Directors.

Senator Kennedy leaves a legacy of unprecedented accomplishment across a remarkably broad spectrum of issues. Foremost among them was his long and productive work on health care, a cause we shared with him.

He was a tireless advocate for patients' rights and for access to quality health care for all. Over the past half century, he was involved in the passage of virtually every piece of major health care legislation, from Medicare in the 1960s to the recent children's health insurance bill.

We were fortunate to have Senator Kennedy visit our facilities to learn about our products and technologies and to thank our employees for all they do to improve patients' lives.

We are profoundly grateful for the opportunity to have known him, to have worked with him and to have been inspired by him.

Our tribute - and pledge - to Senator Kennedy is to continue working relentlessly on behalf of patients, many of whom saw him as their most dedicated champion and for whom medical innovation offers the greatest hope for restored health.

We will miss Senator Kennedy very much.

We extend our deepest sympathies to his family.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

    CONTACT: Paul Donovan
             508-650-8541 (office)
             508-667-5165 (mobile)
             Media Relations
             Boston Scientific Corporation


'/>"/>
SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Boston Scientific to Webcast Conference Call Discussing Results of Landmark MADIT-CRT Trial
2. Boston University Periodontal Study on Imagenetix Compound Published in The Journal of Periodontology
3. Boston Scientific Announces European Approval for Its LATITUDE(R) Patient Management System
4. Boston Scientific to Participate in Wachovia Conference
5. Boston Scientifics SpyGlass(R) Direct Visualization System Featured in Broad Range of Clinical Studies at Upcoming Digestive Disease Week(R)
6. FDA Clears Boston Scientifics SpyScope(R) Access and Delivery Catheter for Use in Endoscopic Procedures Throughout Pancreatico-Biliary System
7. FDA Approves Boston Scientifics Next-Generation TAXUS(R) Liberte(R) Atom(TM) Stent System
8. Angiotechs corporate partner, Boston Scientific, announces launch of third-generation TAXUS(R) Element(TM) Stent
9. Boston Scientific Welcomes Launch of Syntax Score Website
10. Fate Therapeutics Granted Exclusive License for Stem Cell Modulators by Childrens Hospital Boston and Massachusetts General Hospital
11. Boston Scientific to Donate Cardiac Rhythm Management Devices to Heartbeat International for Implantation in Needy Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... While the ... such as the Cary 5000 and the 6000i models are higher end machines that ... the height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and Mold) microbial test has received AOAC Research Institute approval 061601. , “This ... introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. ...
Breaking Biology Technology:
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
(Date:3/31/2016)... 2016  Genomics firm Nabsys has completed a financial ... Bready , M.D., who returned to the company in ... leadership team, including Chief Technology Officer, John Oliver ... Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys from ...
(Date:3/22/2016)... 2016 According to ... for Consumer Industry by Type (Image, Motion, Pressure, ... & IT, Entertainment, Home Appliances, & Wearable ... 2022", published by MarketsandMarkets, the market for ... USD 26.76 Billion by 2022, at a ...
Breaking Biology News(10 mins):